Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1261473 (
sarcoma
)
25,952
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Four patients in whom a diagnosis of acute monocytic leukaemia (M5) was subsequently made presented with extramedullary disease clinically resembling lymphoma. In all patients histological sections were initially misinterpreted as showing malignant lymphoma or anaplastic carcinoma. The diagnosis of M5 leukaemia was subsequently made on the basis of morphological and cytochemical studies of peripheral blood and bone marrow. The histological diagnosis of the soft tissue lesions of M5 leukaemia (monocytic
sarcoma
) is difficult, although features such as abundant cytoplasm and the presence of some reniform nuclei are helpful. If there is no peripheral blood or bone marrow involvement and only fixed paraffin-embedded tissues are available, demonstration of
lysozyme
by an immunoperoxidase technique may confirm the diagnosis but results are not invariably positive. An early diagnosis of M5 leukaemia has therapeutic implications since the disease evolves through a progressive leukaemia phase and systemic therapy is essential.
...
PMID:Lymphoma-like presentation of acute monocytic leukaemia. 657 36
An unusual case of granulocytic
sarcoma
in a 23-year-old man is reported. The patient initially presented with mediastinal tumor and was diagnosed clinically as having thymoma. The patient was treated by radiotherapy and surgical removal of the tumor. Histology of the excised tumor had been nondiagnostic because of extensive fibrous changes. Eight months later, the patient developed pleural effusion on the right, which soon was followed by blood and bone marrow pictures consistent with acute promyelocytic leukemia. In vitro culture of pleural effusion cells unexpectedly gave rise to a continuously growing peroxidase-positive myeloid cell line. Autopsy revealed the recurrent mediastinal tumor to be positive for intracytoplasmic naphthol AS-D chloroacetate esterase and
lysozyme
activity. From these findings, the patient retrospectively was diagnosed as having mediastinal granulocytic
sarcoma
, which terminated in pleural effusion and acute promyelocytic leukemia.
...
PMID:Granulocytic sarcoma presenting as a mediastinal tumor. Report of a case and cytological and cytochemical studies of tumor cells in vivo and in vitro. 659 28
A patient with aleukemic leukemia of the acute granulocytic type, who initially had granulocytic
sarcoma
of the skin, is described. The skin contained focal infiltrates of pleomorphic mononuclear cells that were identified as granulocytes by demonstration of intracytoplasmic naphthol-ASD-chloroacetate esterase and
lysozyme
.
...
PMID:Granulocytic sarcoma of the skin. 693 Sep 36
Effects of
lysozyme
(LY) on immuno-responses were examined. Tumor-bearing mice were used on most of experiments and normal mice on several cases of experiments. Cytostatic activity on the Peyer's patch cells in Meth-A bearing Balb/c mice was enhanced at 6 to 12 hrs after oral administration of LY. Furthermore, LY showed to recover from the decline of blastogenic activity, which was observed on the lymph node cells and the spleen cells of tumor-bearing mice, at 8 and 14 days after tumor inoculation. In the normal ICR mice, it was not observed that LY increased the foot-pad reaction against the sheep red blood cells (SRBC). On the other hand, the decrease of the foot-pad reaction, which was observed in the tumor bearing mice at 20 days after
Sarcoma
-180 (S-180) inoculation, was recovered by the administration of LY. A decrease of the number of plaque-forming cells (PFC) against SRBC which was induced with tumor inoculation in the spleen cells was not observed at 20 days after S-180 inoculation, but LY caused a significant increase of PFC response in spleens on both of normal and tumor bearing mice. From these results, it was suggested that potentiation of systemic immuno-response derived from the activation of Peyer's patches brought about antitumor effects of LY.
...
PMID:[Experimental studies on antitumor effects of lysozyme-II. Effect of lysozyme on immunopotentiation]. 718 77
Effects of
lysozyme
(LY) alone and combination with various antitumor agents were examined using syngeneic tumors mainly Meth-A and MH 134 transplanted into Balb/c and C3H/He mice, respectively. The effects of LY on pulmonary metastases were also examined in BDF1 mice bearing Lewis lung carcinoma (3LL). LY inhibited the growth of Meth-A tumor and enhanced antitumor effects of mitomycin C (MMC). bleomycin (BLM) and 5-fluorouracil (5-FU), LY activated antitumor effects of MMC, BLM and 5-FU on MH 134 tumor, however, LY alone did not show any significant antitumor effect on it. The combination treatments using LY with MMC or 5-FU showed a marked inhibition on pulmonary metastases of 3LL. The pre-treatment of LY inhibited the tumor growth of
Sarcoma
-180 in ICR mice.
...
PMID:[Experimental studies on antitumor effects of lysozyme]. 718 34
Ten tumors of true histiocytic origin (Histiocytic Sarcoma) are presented. The tumor cells were identified as histiocytes by immunological, cytochemical and ultrastructural criteria (cytoplasmic
lysozyme
activity, presence of C3 and Fc gamma receptor, strong acid phosphatase and alpha-naphthyl acetate esterase activity, presence of lysosomes, absence of cell junctions and evidence of phagocytosis). The tumors identified in this way showed the following histological characteristics: diffuse proliferation of large tumor cells with ample cytoplasm, containing granular or occasionally diffuse diastase resistant PAS positive material, erythrophagocytosis, and haemosiderin pigment. The large or enormous nuclei were irregular, with occasional deep indentations, sharply defined nuclear membrane, coarse chromatin and conspicuous nucleoli. Despite the uniformity of these criteria differences in presence of alpha 1-antitrypsin, alpha 1-antichymotrypsin and 5 Nucleotidase activity and the number of lysosomes in the cytoplasm were found. The findings are suggestive of a spectrum of cytological in these Histiocytic
Sarcomas
. The clinical picture ranged from monolocalization in a lymphoid organ to that of a diffuse Malignant Histiocytosis. The relationship between good response to therapy and complete remission and the absence of alpha 1-antitrypsin and a high number of lysosomes is discussed.
...
PMID:Malignant lymphoma of true histiocytic origin: histiocytic sarcoma. A morphological, ultrastructural, immunological, cytochemical and clinical study of 10 cases. 728 92
The diagnosis of primitive hematologic malignancies in extramedullary sites (lymphoblastic lymphoma of T- or B-cell type and myeloid
sarcoma
) on paraffin-embedded tissue sections is difficult and often impossible because of the primitive morphology of the neoplastic cells. The authors studied 21 extramedullary tumors of lymphoid or myeloid blasts. They used a panel of 22 antibodies on frozen sections and 9 antibodies on paraffin sections to determine the spectrum of immunophenotypes and to develop a practical panel for diagnosis. All but two of the cases could be classified as lymphoid or myeloid using immunohistologic analysis. Thirteen cases were classified as lymphoblastic lymphoma/acute lymphoblastic leukemia (LBL/ALL); 10 were classified as precursor T (CD7+, CD3+/-, CD45+) and 3 as precursor B-cell (CD19+/-CD10+CD45-) type. Five cases were classified as myeloid
sarcoma
(CD13+ myeloperoxidase+, lysozyme+). Two LBL/ALL coexpressed either CD33 (1 case) or CD15 (1 case), and one myeloid
sarcoma
coexpressed TdT and CD7. One case appeared to be truly mixed lineage, coexpressing CD3 with myeloperoxidase and
lysozyme
, and two cases expressed no lineage-specific antigens. There were clinical differences between the three major tumor types, and within the category of T-precursor LBL/ALL, classification according to stage of thymocyte differentiation was associated with distinctive clinical features. In conclusion, the spectrum of immunophenotypes detected on frozen section was similar to that reported by flow cytometry on peripheral blood and bone marrow specimens. The most useful antigens on frozen sections were CD7 and CD3 (T cell), CD10 and CD19 (B cell), and CD13 (myeloid). TdT was coexpressed by one myeloid
sarcoma
and was undetectable in 40% of LBL/ALL. On paraffin sections, myeloperoxidase and
lysozyme
were reliable markers of myeloid lineage, but none of the markers used on paraffin sections distinguished between LBL/ALL of T- and B-precursor types. Both B-LBL/ALL and myeloid sarcomas were often CD45- on paraffin sections, which may be a obstacle in determining the diagnosis. These distinctions appear to have clinical relevance.
...
PMID:Extramedullary tumors of lymphoid or myeloid blasts. The role of immunohistology in diagnosis and classification. 757 94
This study investigated the intracellular distribution of
lysozyme
, a protein that is synthesized and secreted by rat alveolar type II epithelial (ATII) cells and alveolar macrophages, using a polyclonal antibody generated against purified rat
lysozyme
. Lysozyme was immunoprecipitated with this antibody from Triton X-100 lysates of ATII cells cultured on a basement membrane derived from Englebreth-Holme-Swarm mouse
sarcoma
(EHS) and radiolabeled with 35S-methionine. ATII cells cultured on EHS basement membrane for several days were fixed and labeled with antibodies to surfactant apoprotein A (SP-A) and lgp-120 (a lysosomal glycoprotein), or
lysozyme
and lgp-120, and studied by confocal microscopy. Organelles were identified that stained positively for either anti-
lysozyme
or anti-lgp-120; a second population of organelles contained both markers. Similarly, two populations of SP-A-containing organelles were identified; one contained the lysosomal glycoprotein lgp-120. In addition, confocal images demonstrated that both SP-A and
lysozyme
were secreted by ATII cells, as evidenced by the accumulation of secretory products within the lumen of the cyst-like aggregates. When the subcellular localization of SP-A and
lysozyme
was studied by analytical cell fractionation, two populations of organelles were identified that contained SP-A or
lysozyme
. The lighter population accounted for approximately 32% of SP-A and 33% of total intracellular
lysozyme
and was recovered in the same region of the gradient as secretory lamellar bodies. The more dense population co-localized with lysosomes and accounted for approximately 67% of both SP-A and
lysozyme
recovered. Western blots of cell fractions revealed intact
lysozyme
in all the cell fractions. The results of these experiments suggest that
lysozyme
has a similar intracellular distribution as surfactant apoprotein A in ATII cells. Lysozyme is found in fractions containing lamellar bodies where it is packaged for secretion, and in lysosomal fractions where it may undergo degradation.
...
PMID:Intracellular distribution of lysozyme in rat alveolar type II epithelial cells. 788 8
Six cases of hepatic
sarcoma
are reported: leiomyosarcoma in two, malignant fibrous histiocytoma in two malignant hemagiopericytoma in one and fibrosarcoma in one. In addition to the routine paraffin section and HE stain, immuno-histochemical studies with antibodies against vimentin, EMA, CK, S100, ACT, AAT, desmin, AFP,
lysozyme
and factor VIII and Masson trichrome staining and argyrophilia staining were done. AFP was negative in all 6 patients and the primary
sarcoma
was characterized by the absence of accompanying liver cirrhosis. The diagnosis, histogenesis and prognosis of primary liver
sarcoma
are discussed.
...
PMID:[Primary sarcoma of the liver]. 795 5
In evaluating histologically malignant infiltrates in the skin, it is often challenging to distinguish granulocytic
sarcoma
(GS) from selected cases of peripheral T-cell lymphoma (PTCL). These lesions have clinical features in common, in addition to shared histologic attributes. These include similarity in dermal distribution and growth pattern, nuclear characteristics, propensity to recruit other inflammatory cell types, and production of matrical sclerosis. In order to determine if immunohistology could contribute to differential diagnosis in this setting, we analyzed 15 cases of mucocutaneous GS, and compared them with 11 cases of well-documented PTCL. Antibodies in the CD15, CD20, CD34, CD43, CD45, CD45RO, and CD68 groups were used, as well as anti-myeloperoxidase (anti-MPX), anti-
lysozyme
(anti-LYSO), Mac387, and MB2. Anti-LYSO and anti-MPX were sensitive and specific markers of GS, labeling 93% and 80% of GS cases, respectively, and no cases of PTCL. Anti-CD15 and MB2 were also specific for GS, but each labeled only 60% of GS cases. CD34, CD68, and Mac 387 were specific but insensitive markers of GS. CD43 and CD45 were not particularly useful discriminants, with each being seen in 93% of GS cases, but also 64% and 100% of cases of PTCL, respectively. CD45RO was specific for PTCL; it was present in 82% of PTCL cases and no GS cases. Thus, conjoint reactivity for CD43, CD45, MPX, and LYSO characterizes GS, and differs from the pattern of PTCL, which is characterized by reactivity for CD45 and CD45RO, occasional reactivity for CD43, and lack of other specified markers.
...
PMID:Granulocytic sarcoma: an immunohistologic comparison with peripheral T-cell lymphoma in paraffin sections. 796 23
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>